NOTCH1 and hepatocellular carcinoma: As a result, it can inhibit the activation of Notch1 pathway and suppresses cell proliferation, migration, invasion, and angiogenesis, thus increasing the sorafenib sensitivity of hepatocellular carcinoma cells.